Schedule 13G ownership disclosure
Celldex Therapeutics Inc
Common Stock, par value $0.001 · CUSIP: 15117B202
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Eventide Asset Management, LLC
Shares: 1,356,186.00 · Class: 2.0%
- Finny Kuruvilla, M.D. Ph. D.
Shares: 1,356,186.00 · Class: 2.0%
- Robin C. John
Shares: 1,356,186.00 · Class: 2.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001580642-25-005132
- Form type
- SCHEDULE 13G/A
- Filer
- Celldex Therapeutics, Inc.
- CIK
- CIK 744218
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership